UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Pharmacological profile of once-weekly injectable semaglutide for chronic weight management

Lau, David CW; Batterham, Rachel L; le Roux, Carel W; (2022) Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. Expert Review of Clinical Pharmacology , 15 (3) pp. 251-268. 10.1080/17512433.2022.2070473. Green open access

[thumbnail of Pharmacological profile of once weekly injectable semaglutide for chronic weight management.pdf]
Preview
PDF
Pharmacological profile of once weekly injectable semaglutide for chronic weight management.pdf - Published Version

Download (1MB) | Preview

Abstract

Introduction: The recent approval in the USA (Food and Drug Administration), Canada (Health Canada), UK (Medicines and Healthcare products Regulatory Agency), and EU (European Medicines Agency) of once-weekly injectable semaglutide 2.4 mg, as an adjunct to a calorie-controlled diet and increased physical activity, for chronic weight management provides health-care practitioners with an additional option when prescribing weight-loss medication. Areas covered: We describe the chemistry, mechanism of action, and pharmacological properties of semaglutide (a glucagon-like peptide 1 receptor agonist [GLP-1 RA]) and discuss clinical data and considerations for using once-weekly subcutaneous semaglutide 2.4 mg as treatment for overweight and obesity among patients with and without type 2 diabetes (T2D). Expert opinion: Once-weekly subcutaneous semaglutide 2.4 mg is the most efficacious medication approved for chronic weight management among patients with overweight and obesity, with and without T2D, and is the first drug to induce sustained double-digit reductions in percentage body weight over 1- to 2-year treatment periods. It demonstrates a similar safety and tolerability profile to other GLP-1 RAs. Semaglutide 2.4 mg treatment could dramatically improve clinical approaches to weight management, but the relatively high cost might prevent patients accessing treatment. Further research exploring the cost-effectiveness of subcutaneous semaglutide 2.4 mg is required.

Type: Article
Title: Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1080/17512433.2022.2070473
Publisher version: https://doi.org/10.1080/17512433.2022.2070473
Language: English
Additional information: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Keywords: Science & Technology, Life Sciences & Biomedicine, Pharmacology & Pharmacy, Anti-obesity medication, diabetes, GLP-1 RAs, obesity, semaglutide 2, 4 mg, weight management, GLUCAGON-LIKE PEPTIDE-1, DOUBLE-BLIND, UPDATED METAANALYSIS, PRACTICE GUIDELINES, AMERICAN-COLLEGE, DOUBLE-DUMMY, BODY-WEIGHT, PHASE 3A, 2.4 MG, OBESITY
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Experimental and Translational Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
URI: https://discovery.ucl.ac.uk/id/eprint/10151895
Downloads since deposit
174Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item